Search Results - "DVIR, Addie"

Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer by Rozenblum, Anna Belilovski, Ilouze, Maya, Dudnik, Elizabeth, Dvir, Addie, Soussan-Gutman, Lior, Geva, Smadar, Peled, Nir

“…Targeted therapy significantly prolongs survival in lung adenocarcinoma. Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor…”
Get more information

Fluorescence In Situ Hybridization, Immunohistochemistry, and Next‐Generation Sequencing for Detection of EML4‐ALK Rearrangement in Lung Cancer by Pekar‐Zlotin, Marina, Hirsch, Fred R., Soussan‐Gutman, Lior, Ilouze, Maya, Dvir, Addie, Boyle, Theresa, Wynes, Murry, Miller, Vincent A., Lipson, Doron, Palmer, Gary A., Ali, Siraj M., Dekel, Shlomi, Brenner, Ronen, Bunn, Paul A., Peled, Nir

“…Background. The U.S. Food and Drug Administration‐approved method for detecting EML4‐ALK rearrangement is fluorescence in situ hybridization (FISH); however,…”
Get full text

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing by Sehayek, Or, Kian, Waleed, Onn, Amir, Stoff, Ronen, Sorotsky, Hadas Gantz, Zemel, Melanie, Bar, Jair, Dudnik, Yulia, Nechushtan, Hovav, Rottenberg, Yakir, Soussan-Gutman, Lior, Dvir, Addie, Roisman, Laila C., Peled, Nir

“…Purpose Molecular profiling is crucial in naïve non-small cell lung cancer (NSCLC). While tissue-based analysis is challenged by turnaround time and scarcity…”
Get full text

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients by Blumenthal, Deborah T., Dvir, Addie, Lossos, Alexander, Tzuk-Shina, Tzahala, Lior, Tzach, Limon, Dror, Yust-Katz, Shlomit, Lokiec, Alejandro, Ram, Zvi, Ross, Jeffrey S., Ali, Siraj M., Yair, Roi, Soussan-Gutman, Lior, Bokstein, Felix

“…Genomic research of high grade glioma (HGG) has revealed complex biology with potential for therapeutic impact. However, the utilization of this information…”
Get full text

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer by MERENBAKH-LAMIN, Keren, BEN-BARUCH, Noa, RIZEL, Shulamith, KLEIN, Baruch, RUBINEK, Tami, WOLF, Ido, YEHESKEL, Adva, DVIR, Addie, SOUSSAN-GUTMAN, Lior, JESELSOHN, Rinath, YELENSKY, Roman, BROWN, Myles, MILLER, Vincent A, SARID, David

“…Resistance to endocrine therapy occurs in virtually all patients with estrogen receptor α (ERα)-positive metastatic breast cancer, and is attributed to various…”
Get full text

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer by JESELSOHN, Rinath, YELENSKY, Roman, ARTEAGA, Carlos L, GILTNANE, Jennifer, BALKO, Justin M, CRONIN, Maureen T, JAROSZ, Mirna, SUN, James, HAWRYLUK, Matthew, LIPSON, Doron, OTTO, Geoff, ROSS, Jeffrey S, BUCHWALTER, Gilles, DVIR, Addie, SOUSSAN-GUTMAN, Lior, WOLF, Ido, RUBINEK, Tamar, GILMORE, Lauren, SCHNITT, Stuart, COME, Steven E, PUSZTAI, Lajos, STEPHENS, Philip, BROWN, Myles, FRAMPTON, Garrett, MILLER, Vincent A, MERIC-BERNSTAM, Funda, GONZALEZ-ANGULO, Ana Maria, FERRER-LOZANO, Jaime, PEREZ-FIDALGO, Jose A, CRISTOFANILLI, Massimo, GOMEZ, Henry

“…We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast…”
Get full text

The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance by Fuchs, Vered, Roisman, Laila, Kian, Waleed, Daniel, Levin, Dudnik, Julia, Nechushtan, Hovav, Goldstein, Iris, Dvir, Addie, Soussan-Gutman, Lior, Grinberg, Roxana, Gillis, Roni, Peled, Nir

“…•Analysis of 30 NGS liquid biopsy tests from EGFRm NSCLC patients at resistance to osimertinib as 1st or 2nd line therapy.•Mechanisms of resistance differed in…”
Get full text

High-confidence AI-based biomarker profiling for H&E slides to optimize pathology workflow in lung cancer by Ofek, Efrat, Haj, Razan, Molchanov, Yossef, Yacobi, Rinat, Mayer, Chen, Barliya, Tilda, Gazy, Inbal, Dvir, Addie, Hayun, Ido, Zalach, Jonathan, Paz Yaacov, Nurit, Peled, Nir, Bar, Jair, Barshack, Iris

“…e21207 Background: In recent years AI methodologies have been increasingly adopted in the oncology space as part of the clinical decision process. Our previous…”
Get full text

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer by Peled, Nir, Roisman, Laila C, Miron, Benjamin, Pfeffer, Raphael, Lanman, Richard B, Ilouze, Maya, Dvir, Addie, Soussan-Gutman, Lior, Barlesi, Fabrice, Tarcic, Gabi, Edelheit, Oded, Gandara, David, Elkabetz, Yehiel

Get more information

Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series by Peled, Michael, Bar, Jair, Avni, Liat, Chatterji, Sumit, Somech, Dafna, Dvir, Addie, Soussan-Gutman, Lior, Onn, Amir

“…Guidelines recommend testing for multiple biomarkers in non-small cell lung cancer (NSCLC) tumors. Blood-based liquid biopsy analyzing cell-free DNA (cfDNA)…”
Get full text

Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry by Shachar, Shlomit, Rizel, Shulamith, Fried, Georgeta, Leviov, Michelle, Yerushalmi, Rinat, Ben-Baruch, Noa, Tokar, Margarita, Soussan-Gutman, Lior, Dvir, Addie, Bareket-Samish, Avital, Yablonski-Peretz, Tamar, Sonnenblick, Amir, Kaufman, Bella, Hammerman, Ariel, Liebermann, Nicky, Stemmer, Salomon M.

“…Abstract only e12587 Background: In the phase 3 TAILORx study, the first invasive disease-free survival event (in all arms) was often opposite BC or other…”
Get full text

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing by Schrock, Alexa B, Frampton, Garrett M, Herndon, Dana, Greenbowe, Joel R, Wang, Kai, Lipson, Doron, Yelensky, Roman, Chalmers, Zachary R, Chmielecki, Juliann, Elvin, Julia A, Wollner, Mira, Dvir, Addie, -Gutman, Lior Soussan, Bordoni, Rodolfo, Peled, Nir, Braiteh, Fadi, Raez, Luis, Erlich, Rachel, Ou, Sai-Hong Ignatius, Mohamed, Mohamed, Ross, Jeffrey S, Stephens, Philip J, Ali, Siraj M, Miller, Vincent A

“…Reliable detection of drug-sensitive activating EGFR mutations is critical in the care of advanced non-small cell lung cancer (NSCLC), but such testing is…”
Get full text

Abstract 5394: The clinical impact of multiplex ctDNA gene analysis in lung cancer by Geva, Smadar, Rozenblum, Anna Belilovski, Twito, Tal, Dvir, Addie, Soussan-Gutman, Lior, Ilouze, Maya, Roisman, Laila C., Dudnik, Elizabeth, Zer, Alona, Lanman, Richard B., Peled, Nir

“…Abstract Background: Next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) enables a non-invasive option for comprehensive genomic…”
Get full text

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC) by Raphael, Ari, Dudnik, Elizabeth, Hershkovitz, Dov, Jain, Suyog, Olsen, Steve, Soussan-Gutman, Lior, Ben-Shitrit, Taly, Dvir, Addie, Nechushtan, Hovav, Peled, Nir, Onn, Amir, Agbarya, Abed, On Behalf Of The Israel Lung Cancer Group

“…fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their…”
Get full text

New paradigm for the treatment of metastatic salivary gland tumors by Popovtzer, Aron, Sarfaty, Michal, Limon, Dror, Marshack, Gideon, Dvir, Addie, Soussan-Gutman, Lior, Stemmer, Salomon M.

“…Abstract only…”
Get full text

RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients by Sarfaty, Michal, Moore, Assaf, Neiman, Victoria, Dudnik, Elizabeth, Ilouze, Maya, Gottfried, Maya, Katznelson, Rivka, Nechushtan, Hovav, Sorotsky, Hadas Gantz, Paz, Keren, Katz, Amanda, Saute, Milton, Wolner, Mira, Moskovitz, Mor, Miller, Vincent, Elvin, Julia, Lipson, Doron, Ali, Siraj, Gutman, Lior Soussan, Dvir, Addie, Gordon, Noa, Peled, Nir

“…Micro-Abstract Data are increasing regarding RET (rearranged during transfection) fusions in lung cancer. We present our experience with the natural history of…”
Get full text

Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel by Yablonski-Peretz, Tamar, Paluch-Shimon, Shani, Gutman, Lior Soussan, Kaplan, Yulia, Dvir, Addie, Barnes-Kedar, Inbal, Kadouri, Luna, Semenisty, Valeriya, Efrat, Noa, Neiman, Victoria, Glasser, Yafit, Michaelson-Cohen, Rachel, Katz, Lior, Kaufman, Bella, Golan, Talia, Reish, Orit, Hubert, Ayala, Safra, Tamar, Yaron, Yuval, Friedman, Eitan

“…We evaluated the clinical utility of screening for mutations in 34 breast/ovarian cancer susceptibility genes in high-risk families in Israel. Participants…”
Get full text

Are all RET fusions NSCLC alike? Clinical pitfalls and response to targeted therapy: KIF5B vs. CCDC6 by Sarfaty, Michal, Moore, Assaf, Gottfried, Maya, Katzenelson, Rivka, Nechushtan, Hovav, Wollner, Mira, Neiman, Victoria, Soussan-Gutman, Lior, Dvir, Addie, Ilouze, Maya, Peled, Nir

“…Abstract only…”
Get full text

Abstract P4-12-09: Low-level constitutional mosaicism of a de novo BRCA1 gene mutation by Friedman, Eitan, Efrat, Noa, Soussan-Gutman, Lior, Dvir, Addie, Kaplan, Yulia, Ekstein, Tali, Nykamp, Keith, Powers, Martin, Rabideau, Marina, Topper, Scott

“…Abstract Background: Germline mutations in the BRCA1 and BRCA2 genes detected in some high-risk breast/ovarian families are used to estimate cancer risk, plan…”
Get full text

Molecular profiling-selected treatment in metastatic gastric and oesophageal cancer: Real-life clinical experience by Purim, Ofer, Beny, Alexander, Inbar, Moshe J., Brenner, Baruch, Dudnik, Elizabeth, Bokstein, Felix, Temper, Mark, Limon, Dror, Sarid, David, Semenisty, Valeriya, Brenner, Ronen Mordechay, Peretz, Tamar, Idelevich, Efraim, Pelles, Sharon, Meirovitz, Amichay, Russell, Kenneth, Voss, Andreas, Dvir, Addie, Soussan-Gutman, Lior, Hubert, Ayala

“…Abstract only e15537 Background: We evaluated real-life clinical experience with molecular profiling (MP)-guided therapy in metastatic gastric and oesophageal…”
Get full text